RNS Number: 8898J Seed Innovations Limited 09 April 2024

9th April 2024

SEED Innovations Limited

("SEED" or the "Company")

Investee Company Update: Northern Leaf plc

SEED Innovations Ltd, the AIM-quoted company investment company providing shareholders with exposure to early-stage health, wellness and medical cannabis companies to which, in normal circumstances, they have limited access to, notes the public announcement by Voyager Life plc ("Voyager") that the merger between themselves and SEED investee company Northern Leaf plc ("Northern Leaf") as announced on 13 March 2024 has been terminated.

Northern Leaf management have advised shareholders that they have taken action to provide short term financing to meet immediate creditor obligations whilst they consider appropriate next steps for the company.

In light of this latest news, SEED expects to carry the investment in Northern Leaf at £nil value in the financial statements of SEED as at 31 March 2024 (previously value indicated to be £13,000 per SEEDs RNS of 22 December 2023).

-Ends-

For further information on the Company please visit: $\underline{www.seedinnovations.co} \text{ or contact:}$

Ed McDermott	SEED Innovations Ltd	E: info@seedinnovations.co
Lance de Jersey		
James Biddle	Beaumont Cornish Limited,	T: (0)20 7628 3396
Roland Cornish	Nomad	
Isabella Pierre	Shard Capital Partners LLP	T: (0)20 7186 9927
Damon Heath	Broker	
Isabel de Salis/Ana Ribeiro/Isabelle Morris	St Brides Partners Ltd, Financial PR	E: seed@stbridespartners.co.uk

Notes

Seed Innovations Ltd

SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact mscane use and distribution of this information may apply. For further information, please contact mscane use and distribution of this information may apply. For further information, please contact mscane use and distribution of this information may apply. For further information, please contact mscane use and distribution of this information may apply.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDSSLFFUELSELL